Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

FDA approves RYZUMVI for presbyopia, expanding Viatris' U.S. ophthalmic portfolio.

What the company is saying

Viatris Inc. is announcing that the FDA has approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults, expanding its U.S. indications beyond pharmacologically-induced mydriasis. The company emphasizes that RYZUMVI remains the only commercially available FDA-approved product for mydriasis, and now holds a unique position for presbyopia as well. Viatris highlights its exclusive U.S. commercialization rights under a global licensing agreement with Opus Genetics. The release frames this as a significant regulatory milestone and signals intent to seek a U.S. commercialization partner for the new indication. Clinical data is presented with specific adverse event rates, and the majority of side effects are described as mild and self-resolving. The tone is confident and factual, focusing on regulatory achievement and clinical differentiation rather than financial projections.

What the data suggests

The FDA approval for RYZUMVI in presbyopia is a realised regulatory milestone, not a projection. The product is formulated as phentolamine ophthalmic solution 0.75%. For presbyopia, the most common ocular adverse reactions were conjunctival hyperemia (21%) and instillation site irritation (16%). For mydriasis, instillation site discomfort (pain, stinging, burning) occurred in 16% and conjunctival hyperemia in 12% of subjects. The only non-ocular adverse event above 5% was dysgeusia at 6%. Most adverse reactions were mild, transient, and self-resolving, though no quantitative breakdown is provided for severity. The product is also indicated for pediatric patients aged 3 years and older for mydriasis. No financial data, revenue projections, or launch timelines are disclosed. The announcement is specific on clinical and regulatory facts but does not quantify commercial opportunity or expected uptake.

Analysis

The announcement is factual and proportionate, focusing on the FDA approval of RYZUMVI for presbyopia, which is a realised regulatory milestone. The majority of claims are realised and supported by specific clinical and regulatory data, including adverse event rates and product indications. The only forward-looking statement is that Viatris is exploring a commercialization partner in the United States for the new indication, but no financial projections, timelines, or capital outlays are disclosed. There is no evidence of narrative inflation or exaggerated claims; the tone is positive but not promotional. However, the absence of any financial or profitability metrics means the investment impact cannot be fully assessed, capping the true_signal at weak_positive. The execution distance for commercial benefits is unknown, as no launch or revenue timeline is provided.

Risk flags

• ●Commercialization risk is high, as Viatris has not yet secured a U.S. partner to market RYZUMVI for presbyopia. Without a partner or internal launch plan, market entry and uptake are uncertain.
• ●No revenue, sales, or market size projections are disclosed for the new indication, making it difficult to assess the financial impact or potential return on investment.
• ●Adverse reaction rates for conjunctival hyperemia (21%) and instillation site irritation (16%) in presbyopia patients may affect patient and physician acceptance, especially in a competitive ophthalmic market.

Bottom line

Viatris has achieved FDA approval for RYZUMVI in presbyopia, adding to its existing mydriasis indication and reinforcing its position in the U.S. ophthalmic market. The clinical data is specific, with adverse event rates of 21% for conjunctival hyperemia and 16% for instillation site irritation in presbyopia, and 16% for instillation site discomfort and 12% for conjunctival hyperemia in mydriasis. The company holds exclusive U.S. commercialization rights through a licensing agreement with Opus Genetics but has not yet secured a partner or disclosed a launch plan for the new indication. No financial or market uptake data is provided, so the commercial impact remains unquantified. The main value driver will be successful commercialization and market adoption, which are not guaranteed at this stage. Investors should focus on future updates regarding partnerships, launch timelines, and initial sales figures. The key takeaway is that regulatory risk is now removed, but execution and market risks remain.

Announcement summary

(NASDAQ:VTRS) Viatris Inc. announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is already approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that indication. This new approval expands RYZUMVI's indications to include presbyopia. Viatris is currently exploring the potential for a partner in the United States to commercialize RYZUMVI for presbyopia. Opus Genetics and Viatris Inc. (through an affiliated entity) are parties to a global licensing agreement for the development of phentolamine ophthalmic solution 0.75%, which grants Viatris exclusive rights to commercialize the product in the United States. Presbyopia is described as the gradual loss of near focusing ability due to aging, typically becoming noticeable in the early to mid-40s, and is a nearly universal condition that can significantly impact daily tasks and productivity. RYZUMVI (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of presbyopia in adults and for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents in adults and pediatric patients 3 years of age and older. The most common ocular adverse reactions reported in more than 5% of subjects treated for presbyopia were conjunctival hyperemia (21%) and instillation site irritation (16%). For pharmacologically-induced mydriasis, the most common ocular adverse reactions reported in more than 5% of subjects were instillation site discomfort including pain, stinging, and burning (16%) and conjunctival hyperemia (12%). The only non-ocular adverse reaction reported in more than 5% of subjects was dysgeusia (6%). The majority of adverse reactions were mild, transient, and self-resolving. RYZUMVI is not recommended for use in patients with active ocular inflammation such as iritis. Contact lens wearers should remove their lenses prior to instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses. Viatris Inc. is headquartered in the United States, with global centers in Pittsburgh, Shanghai, and Hyderabad, India.

Disagree with this article?